Yue Cao
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (6)
Purpose: We conducted a phase II multicenter clinical trial to test the hypothesis that 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET)–based chemoradiation (CRT) dose deescalation would provide noninferior locoregional control compared with historical controls among patients with early-stage p16+ oropharyngeal cancer. We also hypothesized that human papillomavirus (HPV) circulating tumor DNA (ctDNA) changes during treatment predict locoregional recurrence (LRR). Patients and Methods: Patients with stage I/II p16+ oropharyngeal squamous cell carcinoma were planned to receive radiation 70 Gy in 35 fractions with concurrent weekly carboplatin and paclitaxel. All patients underwent FDG-PET at baseline and at radiation therapy (RT) fraction 10. Patients with ≥50% decrease from baseline to mid-treatment metabolic tumor volume had treatment deescalated to 54 Gy in 27 fractions. The primary endpoint was LRR. Plasma HPV ctDNA was evaluated weekly and in surveillance. Results: Of 84 evaluable patients, 43% met deescalation criteria. With a median follow-up of 37.8 months, 24-month LRR for the entire cohort was 7.8% [90% confidence interval (CI), 2.6%–12.6%], which was less than the 25% rate specified for assessing noninferiority, thereby meeting the primary endpoint. At 1 month after RT, the mean of multiple quality of life measures between the two groups was improved in the 54 Gy cohort, exceeding the minimal clinically important difference threshold. During CRT, week 1 percentage increase in ctDNA relative to baseline was significantly associated with worse loco-regional control (LRC; HR = 1.052 per 10 percentage point increase in ctDNA; 95% CI, 1.007–1.099; P = 0.023) and loco-regional progression-free survival (HR = 1.038; 95% CI, 1.002–1.076; P = 0.035). Conclusions: FDG-PET–based RT dose personalization resulted in promising LRR outcomes in early-stage oropharynx cancer with improved short-term patient-reported outcomes. Furthermore, HPV ctDNA changes early in treatment may predict LRC.
Year:
2026
Odds ratios (OR) and p values for multi-variable models for acute and late toxicity outcomes including covariates of p16+ OPSCC vs LAHNSCC, primary tumor volume (GTVp) and RT boost volume treated.
Year:
2025
KM curves of average patient p16+ and p16- LRF outcomes. Plot for estimated incidence of loco-regional failure (LRF) with the median boost volume (6.9cc) and GTV primary (54.8cc) for: p16+ OPSCC (left panel) and LAHNSCC (right panel).
Year:
2025
Purpose: We hypothesized that optimizing the utility of stereotactic body radiotherapy (SBRT) based on the individual patient's probability for tumor control and risk of liver injury would decrease toxicity without sacrificing local control in patients with impaired liver function or tumors not amenable to thermal ablation. Patients and Methods: Patients with Child-Pugh (CP) A to B7 liver function with aggregate tumor size >3.5 cm, or CP ≥ B8 with any size tumor were prospectively enrolled on an Institutional Review Board–approved phase II clinical trial to undergo SBRT with baseline and midtreatment dose optimization using a quantitative, individualized utility-based analysis. Primary endpoints were change in CP score of ≥2 points within 6 months and local control. Protocol-treated patients were compared with patients receiving conventional SBRT at another cancer center using overlap weighting. Results: A total of 56 patients with 80 treated tumors were analyzed with a median follow-up of 11.2 months. Two-year cumulative incidence of local progression was 6.4% [95% confidence interval (CI, 2.4–13.4)]. Twenty-one percent of patients experienced treatment-related toxicity within 6 months, which is similar to the rate for SBRT in patients with CP A liver function. An analysis using overlap weighting revealed similar local control [HR, 0.69; 95% CI (0.25–1.91); P = 0.48] and decreased toxicity [OR, 0.26; 95% CI (0.07–0.99); P = 0.048] compared with conventional SBRT. Conclusions: Treatment of individuals with impaired liver function or tumors not amenable to thermal ablation with a treatment paradigm designed to optimize utility may decrease treatment-related toxicity while maintaining tumor control.
Year:
2025
Purpose: We hypothesized that optimizing the utility of stereotactic body radiation therapy (SBRT) based on the individual patient’s probability for tumor control and risk of liver injury would decrease toxicity without sacrificing local control in patients with impaired liver function or tumors not amenable to thermal ablation. Methods: Patients with Child-Pugh (CP) A to B7 liver function with aggregate tumor size >3.5 cm, or CP ≥ B8 with any size tumor were prospectively enrolled on an IRB approved phase II clinical trial to undergo SBRT with baseline and mid-treatment dose optimization using a quantitative, individualized utility-based analysis. Primary endpoints were change in CP score of ≥2 points within 6 months and local control. Protocol-treated patients were compared with patients receiving conventional SBRT at another cancer center using overlap weighting. Results: 56 patients with 80 treated tumors were analyzed with a median follow-up of 11.2 months. Two-year cumulative incidence of local progression was 6.4% (95% CI [2.4 – 13.4]). 21% of patients experienced treatment-related toxicity within 6 months, which is similar to the rate for SBRT in patients with CP A liver function. An analysis using overlap weighting revealed similar local control (HR 0.69, 95% CI [0.25-1.91], p = 0.48) and decreased toxicity (OR 0.26, 95% CI [0.07 – 0.99], p = 0.048) compared to conventional SBRT. Conclusion: Treatment of individuals with impaired liver function or tumors not amenable to thermal ablation with a treatment paradigm designed to optimize utility may decrease treatment-related toxicity while maintaining tumor control.
Year:
2024
Purpose: We conducted a randomized phase II multicenter clinical trial to test the hypothesis that physiologic MRI-based radiotherapy (RT) dose escalation would improve the outcome of patients with poor prognosis head and neck cancer. Patients and Methods: MRI was acquired at baseline and at RT fraction 10 to create low blood volume/apparent diffusion coefficient maps for RT boost subvolume definition in gross tumor volume. Patients were randomized to receive 70 Gy (standard RT) or 80 Gy to the boost subvolume (RT boost) with concurrent weekly platinum. The primary endpoint was disease-free survival (DFS) with significance defined at a one-sided 0.1 level, and secondary endpoints included locoregional failure (LRF), overall survival (OS), comparison of adverse events and patient reported outcomes (PRO). Results: Among 81 randomized patients, neither the primary endpoint of DFS (HR = 0.849, P = 0.31) nor OS (HR = 1.19, P = 0.66) was significantly improved in the RT boost arm. However, the incidence of LRF was significantly improved with the addition of the RT boost (HR = 0.43, P = 0.047). Two-year estimates [90% confidence interval (CI)] of the cumulative incidence of LRF were 40% (27%–53%) in the standard RT arm and 18% (10%–31%) in the RT boost arm. Two-year estimates (90% CI) for DFS were 48% (34%–60%) in the standard RT arm and 57% (43%–69%) in the RT boost arm. There were no significant differences in toxicity or longitudinal differences seen in EORTC QLQ30/HN35 subscales between treatment arms in linear mixed-effects models. Conclusions: Physiologic MRI-based RT boost decreased LRF without a significant increase in grade 3+ toxicity or longitudinal PRO differences, but did not significantly improve DFS or OS. Additional improvements in systemic therapy are likely necessary to realize improvements in DFS and OS.
Year:
2022
Collaborators (18)
Charles Mayo
University of Michigan
Steven B. Chinn
Assistant Professor
University of Michigan
Mishal Mendiratta‐Lala
-
Kyle Cuneo
Associate Professor
Michigan Medicine
Neehar D. Parikh
University of Michigan
Marisa Buchakjian
Assistant Professor
University of Iowa Hospitals and Clinics
Keith Casper
-
Matthew J. Schipper
University of Michigan
Dawn Owen
Professor/Consultant
Mayo Clinic Rochester
Muneesh Tewari
Associate Professor
University of Michigan
Michael Yan
Radiation Oncologist
University Health Network
Matthew E. Spector
University of Pittsburgh Medical Center
Paul Swiecicki
University of Michigan
Krithika Suresh
Research Assistant Professor
University of Michigan
Andrew Rosko
University of Michigan
THEODORE S. LAWRENCE
Chair, Professor
University of Michigan
J. Chad Brenner
Director Head and Neck Oncology Program
University of Michigan
Randall Ten Haken
Professor
University of Michigan Medical School
Make your next move.
Prepare your application
Review drafts before you send them.